Analysis of United States Patent 4,818,816: Scope, Claims, and Landscape
United States Patent 4,818,816, granted on April 11, 1989, to Merck & Co., Inc., covers a class of novel compounds and their use in treating hypertension and other cardiovascular conditions. The patent's core innovation lies in Angiotensin-Converting Enzyme (ACE) inhibitors with specific structural modifications that enhance potency and duration of action. This analysis details the patent's claims, its scope, and the surrounding patent landscape.
What Compounds Does Patent 4,818,816 Claim?
Patent 4,818,816 claims a genus of N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline derivatives. The patent defines these compounds through a Markush structure with specific variable substituents.
The core structure is represented by the formula:
R1
|
R-C-NH-CH-CO-N-CH2-CH2
| | | \
CH2 CH3 CH CH2
| |
C6H5 COOH
Where:
- R is selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms.
- R1 is selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms.
- The compound is an L-alanyl-L-proline derivative.
Specifically, the patent focuses on compounds where the N-(1-carboxy-3-phenylpropyl) group is attached to the L-alanyl-L-proline dipeptide moiety. The phenylpropyl group provides a critical lipophilic interaction within the ACE active site, while the alanine and proline residues mimic the natural substrates of the enzyme.
The patent includes 38 specific exemplified compounds, each with defined R and R1 groups. These exemplified compounds represent specific embodiments of the claimed genus. For example, Example 1 describes the synthesis of N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline, a key compound within the claimed series. Other examples detail variations in the alkyl substituents at the R and R1 positions.
What Therapeutic Applications Are Covered by the Patent?
The primary therapeutic application claimed for the compounds of patent 4,818,816 is the treatment of hypertension. The patent posits that these compounds are potent inhibitors of Angiotensin-Converting Enzyme (ACE). By inhibiting ACE, these compounds prevent the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduction in angiotensin II levels leads to vasodilation and a subsequent decrease in blood pressure.
Beyond hypertension, the patent also claims the use of these compounds in treating:
- Congestive heart failure
- Renal hypertension
- Secondary hyperaldosteronism
- The diagnosis of low-renin hypertension
- Other conditions where ACE inhibition is beneficial.
The patent describes a method of treating these conditions by administering a therapeutically effective amount of a compound according to the claimed formula. The dosage ranges specified are typically between 1 to 100 mg per day for oral administration, depending on the specific compound and the condition being treated.
What Is the Scope of the Patent's Claims?
The scope of patent 4,818,816 is defined by its independent and dependent claims. The independent claims are broad and encompass a wide range of chemical structures and therapeutic uses.
Key Claims:
- Claim 1 (Independent): This is the broadest claim, defining the genus of N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline derivatives as described above. It covers any compound fitting the general formula with the specified variations for R and R1.
- Claim 2 (Dependent): This claim recites R being hydrogen.
- Claim 3 (Dependent): This claim recites R1 being hydrogen.
- Claim 4 (Dependent): This claim recites both R and R1 being hydrogen, specifically referring to N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline.
- Claim 5 (Independent): This claim covers pharmaceutical compositions comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This broadens the patent's reach to include any formulation containing the active ingredient.
- Claim 6 (Independent): This claim covers the method of treating hypertension by administering a compound of Claim 1.
- Claim 7 (Dependent): This claim specifies the method of treating congestive heart failure.
- Claim 8 (Dependent): This claim specifies the method of treating renal hypertension.
The scope of the patent is significant because it covers a class of compounds, not just a single molecule. This "genus" claim provides broad protection, encompassing numerous potential drug candidates that fall within the defined chemical space. The patent's claims for pharmaceutical compositions and therapeutic methods further solidify its protection over the commercialization of these ACE inhibitors.
The patent does not explicitly claim methods of synthesis, but rather the compounds themselves and their uses. However, the exemplified synthesis procedures within the patent can inform the development of manufacturing processes for the claimed compounds.
What Is the Patent Landscape for ACE Inhibitors Around 1989?
The filing and issuance of patent 4,818,816 occurred within a period of intense research and development in the field of cardiovascular therapeutics, specifically for ACE inhibitors. By the late 1980s, the first generation of ACE inhibitors, such as Captopril (marketed as Capoten by Bristol-Myers Squibb) and Enalapril (marketed as Vasotec by Merck & Co.), were already established.
- Captopril: Patented by Squibb (later Bristol-Myers Squibb), its initial patents would have been nearing expiration or expired by this time, creating an opportunity for new entrants and next-generation compounds.
- Enalapril: Developed by Merck & Co., and a significant blockbuster drug, Enalapril was also protected by patents that were maturing. Enalapril is structurally related to the compounds in patent 4,818,816, featuring a similar dipeptide mimic structure but with different substituents.
The landscape was characterized by:
- Follow-on Innovation: Companies were actively seeking to develop improved ACE inhibitors with better pharmacokinetic profiles (e.g., longer half-life, reduced dosing frequency), enhanced efficacy, and fewer side effects (e.g., cough, angioedema).
- Patent Races: The success of early ACE inhibitors spurred significant patenting activity to capture market share for next-generation therapies. Merck & Co., as the assignee of patent 4,818,816, was a major player in this field.
- Focus on Specific Substructures: The development of ACE inhibitors often involved modifying known pharmacophores. Patent 4,818,816 represents such an effort to explore variations on the established ACE inhibitor template. The N-(1-carboxy-3-phenylpropyl) moiety is a direct structural evolution from the core found in enalaprilat and enalapril.
The existence of patent 4,818,816 suggests Merck & Co. was strategically expanding its ACE inhibitor portfolio. The compounds claimed in this patent likely aimed to offer distinct advantages over existing drugs, potentially related to improved oral bioavailability, longer duration of action, or a different side effect profile. The patent's claims are broad enough to cover a class of compounds, indicating a strategy to secure intellectual property around a chemical space that held promise for novel therapeutics.
Key Takeaways
- Patent 4,818,816 protects a genus of novel ACE inhibitor compounds with a specific N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline derivative structure.
- The claimed compounds are indicated for the treatment of hypertension, congestive heart failure, and other cardiovascular conditions.
- The patent includes broad claims covering the chemical compounds, pharmaceutical compositions containing them, and methods of therapeutic use.
- The patent was filed and granted during a period of significant innovation and patent activity in the ACE inhibitor market, with Merck & Co. being a prominent innovator.
FAQs
-
What is the principal therapeutic benefit claimed for the compounds in patent 4,818,816?
The principal therapeutic benefit claimed is the treatment of hypertension through the inhibition of Angiotensin-Converting Enzyme (ACE).
-
Are the specific compounds claimed in patent 4,818,816 still under patent protection?
The patent was granted on April 11, 1989. In the United States, utility patents typically have a term of 17 years from the date of grant or 20 years from the date of filing, whichever is longer, subject to maintenance fees. Therefore, patent 4,818,816 expired by at least 2006 (17 years from grant).
-
Does patent 4,818,816 cover the synthesis of these ACE inhibitors?
The patent primarily claims the compounds themselves and their therapeutic uses. While it provides examples of synthetic routes, it does not claim the general methods of synthesis broadly.
-
What is the structural difference between the compounds in patent 4,818,816 and Enalapril?
Enalapril is N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline. Patent 4,818,816 covers N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline derivatives where the carboxy group is free or substituted with a small alkyl group, and the phenylpropyl chain can also bear small alkyl substituents. Enalapril is an ester prodrug of an active diacid form, whereas patent 4,818,816's primary focus is on the diacid or its simple alkyl ester forms.
-
Who was the assignee of patent 4,818,816?
The assignee of patent 4,818,816 was Merck & Co., Inc.
Citations
[1] Merck & Co., Inc. (1989). N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline derivatives. U.S. Patent 4,818,816. Washington, DC: U.S. Patent and Trademark Office.
